adopted heme‐albumin, which can induce heme oxygenase‐1 (HO‐1) to provide anti‐inflammatory protection in RPE cells, integrated into PDA nanoparticles, contributing to heme‐albumin sustainedly release for up to six months, even with quicker release observed under higher oxidative stress conditions.[103] Intriguingly, an innovative melanin‐compensatory therapeutic strategy for AMD was developed recently.[104] Melanin is naturally present in RPE cells to help counteract oxidative stress, but its antioxidant capacities deplete with the aging process. The gene discussed is ALB; the disease is age-related macular degeneration.